Pursuant to 37 C.F.R. 1.71(e), applicants note that a portion of this disclosure contains material that is subject to copyright protection (such as, but not limited to, diagrams, device photographs, or any other aspects of this submission for which copyright protection is or may be available in any jurisdiction). The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.
The invention in various embodiments relates to handling of micro-objects, such as cells or micro-fabricated particles are beads, using a microfluidic system and particularly is directed to a configuration that can be used with various standard automated handling systems. In particular embodiments, the invention involves an automated system for cell culture.
The discussion of any work, publications, sales, or activity anywhere in this submission, including in any documents submitted with this application, shall not be taken as an admission that any such work constitutes prior art. The discussion of any activity, work, or publication herein is not an admission that such activity, work, or publication existed or was known in any particular jurisdiction.
Microfluidic cell culture is a promising technology for applications in the drug screening industry. Key benefits include improved biological function, higher-quality cell-based data, reduced reagent consumption, and lower cost. High quality molecular and cellular sample preparations are important for various clinical, research, and other applications. In vitro samples that closely represent their in vivo characteristics can potentially benefit a wide range of molecular and cellular applications. Handling, characterization, culturing, and visualization of cells or other biologically or chemically active materials (such as beads coated with various biological molecules) has become increasingly valued in the fields of drug discovery, disease diagnoses and analysis, and a variety of other therapeutic and experimental work.
Mammalian cell culture is particularly challenging, particularly for maintaining effective solid aggregates of cells in culture. Advances have been made by adapting various microfabrication and microfluidic technologies to cell culture, though there remains an ongoing need for a device that can be economically manufactured and used to provide effective cell culture.
Publications and/or patent documents that discuss various strategies related to cell culture using microfluidic systems and related activities include the following U.S. patent applications and non-patent literature, which, along with all citations therein, are incorporated herein by reference for all purposes. A listing of these references here does not indicate the references constitute prior art.
Cytoplex, Inc. U.S. Pat. No. 6,653,124 “Array-based microenvironment for cell culturing, cell monitoring and drug-target validation.”
Cellomics, Inc. U.S. Pat. No. 6,548,263 “Miniaturized cell array methods and apparatus for cell-based screening.”
Fluidigm, Inc. Published Application 20040229349 (Nov. 18, 2004) “Microfluidic particle-analysis systems.”
1. T. H. Park and M. L. Shuler, Biotechnol. Prog., 2003, 19, 243.
2. G. M. Walker, H. C. Zeringue and D. J. Beebe, Lab Chip, 2004, 4, 91.
3. E. Leclerc, Y. Sakai and T. Fujii, Biotechnol. Prog., 2004, 20, 750.
4. M. J. Powers, K. Domansky, M. R. Kaazempur-Mofrad, A. Kalezi, A. Capitano, A. Upadhyaya, P. Kurzawski, K. E. Wack, D. B. Stolz, R. Kamm and L. G. Griffith, Biotechnol. Bioeng., 2002, 78, 257.
5. K. Viravaidya and M. L. Shuler, Biotechnol. Prog., 2004, 20, 590.
6. Y. Kostov, P. Harms, L. Randers-Eichhorn and G. Rao, Biotechnol. Bioeng., 2001, 72, 346.
7. N. Li Jeon, H. Baskaran, S. K. Dertinger, G. M. Whitesides, L. Van der Water and M. Toner, Nat. Biotechnol., 2002, 20, 826.
8. T. Thorsen, S. J. Maerkl and S. R. Quake, Science, 2002, 298, 580.
9. H. Andersson and A. van den Berg, Lab Chip, 2004, 4, 98.
10. Dove, A. (2003) Nature Biotechnology 21, 859-864.
11. Entzeroth, M. (2003) Current Opinion in Pharmacology 3, 522-529.
12. Boess, F.; Kamber, M.; Romer, S.; Gasser, R.; Muller, D.; Albertini, S.; Suter, L. Toxicol Sci 2003, 73, (2), 386-402.
13. Rodriguez-Antona, C.; Donato, M. T.; Boobis, A.; Edwards, R. J.; Watts, P. S.; Castell, J. V.; Gomez-Lechon, M. J. Xenobiotica 2002, 32, (6), 505-20.
14. Cukierman, E.; Pankov, R.; Stevens, D. R.; Yamada, K. M. Science 2001, 294, (5547), 1708-12.
15. Griffith, L. G.; Swartz, M. A. Nat Rev Mol Cell Biol 2006, 7, (3), 211-24.
16. Revzin, A.; Rajagopalan, P.; Tilles, A. W.; Berthiaume, F.; Yarmush, M. L.; Toner, M. Langmuir 2004, 20, (8), 2999-3005.
17. Flaim, C. J.; Chien, S.; Bhatia, S. N. Nat Methods 2005, 2, (2), 119-25.
18. Anderson, D. G.; Levenberg, S.; Langer, R. Nat Biotechnol 2004, 22, (7), 863-6.
19. Battle, T.; Stacey, G. Cell Biol Toxicol 2001, 17, (4-5), 287-99.
20. LeCluyse, E. L.; Bullock, P. L.; Parkinson, A. Advanced Drug Delivery Reviews 1996, (22), 133-186.
21. Ben-Ze'ev, A.; Robinson, G. S.; Bucher, N. L.; Farmer, S. R. Proc Natl Acad Sci USA 1988, 85, (7), 2161-5.
22. Bhatia, S. N.; Balis, U. J.; Yarmush, M. L.; Toner, M. Faseb J 1999, 13, (14), 1883-900.
23. Berthiaume, F.; Moghe, P. V.; Toner, M.; Yarmush, M. L. Faseb J 1996, 10, (13), 1471-84.
24. Stevens, M. M.; George, J. H. Science 2005, 310, (5751), 1135-8.
25. Bissell, M. J.; Rizki, A.; Mian, I. S. Curr Opin Cell Biol 2003, 15, (6), 753-62.
26. Allen, J. W.; Bhatia, S. N. Biotechnol Bioeng 2003, 82, (3), 253-62.
27. Hung, P. J.; Lee, P. J.; Sabounchi, P.; Aghdam, N.; Lin, R.; Lee, L. P. Lab Chip 2005, 5, (1), 44-8.
28. Lee, P. J.; Hung, P. J.; Rao, V. M.; Lee, L. P. Biotechnol Bioeng 2005.
29. Puhl, G.; Schaser, K. D.; Vollmar, B.; Menger, M. D.; Settmacher, U. Transplantation 2003, 75, (6), 756-61.
30. Park, J.; Berthiaume, F.; Toner, M.; Yarmush, M. L.; Tilles, A. W. Biotechnol Bioeng 2005, 90, (5), 632-44.
31. Anderson, K.; Wilkinson, R.; Grant, M. H. Int J Artif Organs 1998, 21, (6), 360-4.
32. Landry, J.; Bernier, D.; Ouellet, C.; Goyette, R.; Marceau, N. J Cell Biol 1985, 101, (3), 914-23.
33. A. Ben-Ze'ev, G. S. Robinson, N. L. Bucher, S. R. Farmer, Proc Natl Acad Sci USA 85, 2161 (April, 1988).
34. J. Landry, D. Bernier, C. Ouellet, R. Goyette, N. Marceau, J Cell Biol 101, 914 (September, 1985).
35. S. A. Stoehr, H. C. Isom, Hepatology 38, 1125 (November, 2003).
36. Zhang, X, Wang, W, Yu, W, Xie, Y, Zhang, X, Zhang, Y, Ma, X. Biotechnol Prog 2005, 21, 1289-96.
37. Kelm, J, Timmins, N, Brown, C, Fussenegger, M, Nielsen, L. Biotechnology and Bioengineering. 2003, 83(2)173-180.
38. Kuns-Schughart, L, Freyer, J, Hofstaedter, F, Ebner, R. J. Biomolecular Screening. 2004, 9(4) 273-285.
Earlier work and patent documents as cited above involving at least one of the present inventors discuss various configurations, methods, and systems related to microfluidic cell culture and that earlier work and those patent documents are incorporated herein by reference.
The present invention involves various components, systems, and methods related to improved microfluidic cell culture systems. In one aspect, the invention involves novel microfluidic cell culture systems and methods that have advantages over previously proposed microfluidic structures. In another aspect, the invention involves novel structures and methods for integrating multiple microfluidic cell culture systems to a microtiter well plate structure, such as a standard culture-well plate formats (e.g., a 96-well SBS culture plate). In a further aspect, the invention involves novel fabrication methods for creating an array of microfluidic cell culture areas suitable for integration with a well plate. In another aspect, the invention involves novel systems, methods, and components for an improved automated high-throughput cell culture and/or screening system using microfluidic cell cultures
In particular embodiments, key design features include the elimination of tubing and connectors to the plates themselves, the ability to maintain long-term continuous perfusion cell culture using a passive gravity-driven flow, and direct analysis on the outlet wells and/or cellular observation wells of the microfluidic plate.
For purposes of clarity, this discussion refers to devices, methods, and concepts in terms of specific examples. However, the invention and aspects thereof may have applications to a variety of types of devices and systems. It is therefore intended that the invention not be limited except as provided in the attached claims and equivalents.
Furthermore, it is well known in the art that systems and methods such as described herein can include a variety of different components and different functions in a modular fashion. Different embodiments of the invention can include different mixtures of elements and functions and may group various functions as parts of various elements. For purposes of clarity, the invention is described in terms of systems that include many different innovative components and innovative combinations of innovative components and known components. No inference should be taken to limit the invention to combinations containing all of the innovative components listed in any illustrative embodiment in this specification.
In some of the drawings and detailed descriptions below, the present invention is described in terms of the important independent embodiment of a complete, fully automated, cellular culture system and components thereof. This should not be taken to limit various novel aspects of the invention, which, using the teachings provided herein, can be applied to a number of other situations. In some of the drawings and descriptions below, the present invention is described in terms of a number of specific example embodiments including specific parameters related to dimensions of structures, pressures or volumes of liquids, temperatures, electrical values, and the like. Except where so provided in the attached claims, these parameters are provided as examples and do not limit the invention to other devices or systems with different dimensions. For purposes of providing an more illuminating description, particular known fabrication steps, cell handling steps, reagents, chemical or mechanical process, and other known components that may be included to make a system or manufacture a device according to specific embodiments of the invention are given as examples. It will be understood to those of skill in the art that except were specifically noted herein otherwise, various known substitutions can be made in the processes described herein.
All references, publications, patents, and patent applications cited in this submission are hereby incorporated by reference in their entirety for all purposes.
1. Overview
Definitions
A “particle” refers to biological cells, such as mammalian or bacterial cells, viral particles, or liposomal or other particles that may be subject to assay in accordance with the invention. Such particles have minimum dimensions between about 50-100 nm, and may be as large as 20 microns or more. When used to describe a cell assay in accordance with the invention, the terms “particles” and “cells” may be used interchangeably.
A “microwell” refers to a micro-scale chamber able to accommodate a plurality of particles. A microwell is typically cylindrical in shape and has diameter and depth dimensions in a preferred embodiment of between 100 and 1500 microns, and 10 and 500 microns, respectively. When used to refer to a microwell within the microwell array device of the invention, the term “well” and “microwell” are used interchangeably.
A “microchannel” refers to a micron-scale channel used for connecting a station in the device of the invention with a microwell, or a station and a valve associated with the microwell. A microchannel typically has a rectangular, e.g., square cross-section, with side and depth dimensions in a preferred embodiment of between 10 and 500 microns, and 10 and 500 microns, respectively. Fluids flowing in the microchannels may exhibit microfluidic behavior. When used to refer to a microchannel within the microwell array device of the invention, the term “microchannel” and “channel” are used interchangeably.
A “microfluidics device” refers to a device having various station or wells connected by micron-scale microchannels in which fluids will exhibit microfluidic behavior in their flow through the channels.
A “microwell array” refers to an array of two or more microwells formed on a substrate.
A “device” is a term widely used in the art and encompasses a broad range of meaning. For example, at its most basic and least elaborated level, “device” may signify simply a substrate with features such as channels, chambers and ports. At increasing levels of elaboration, the “device” may further comprise a substrate enclosing said features, or other layers having microfluidic features that operate in concert or independently. At its most elaborated level, the “device” may comprise a fully functional substrate mated with an object that facilitates interaction between the external world and the microfluidic features of the substrate. Such an object may variously be termed a holder, enclosure, housing, or similar term, as discussed below. As used herein, the term “device” refers to any of these embodiments or levels of elaboration that the context may indicate.
Microfluidic systems provide a powerful tool to conduct biological experiments. Recently, elastomer-based microfluidics has especially gained popularity because of its optical transparency, gas permeability and simple fabrication methods. However, the interface with the end-users requires labor-intensive hole punching through the elastomer, and additional steps of tubing and syringe pump connection.
The present invention involves integrated elastomer-based microfluidics on standard well plates, with special focus on hepatocyte culture applications. The invention further involves methods of manufacture of such plates and components and a system for automating cell culture using such plates. Advantages of specific embodiments include use of a standard microtiter plate format, tubing free cell culture, and a biomimetic liver microenvironment.
A system according to specific embodiments of the invention (for example, using 96-well standard plates) can be operated using standard techniques and equipment for handling standard microtiter plates, as are well known in the art. For example, liquid dispensing is achieved with standard pipette mechanics, and cell culture and analysis can be made compatible with existing incubators and plate readers.
According to further embodiments of the invention, a novel cell loading system uses a pneumatic manifold and pneumatic pressure to place cells in the micro culture area. With the addition of this cell loading system, microfluidic cell culture and analysis can be fully automated using other automated equipment that exists for handling standard titer plates.
In further embodiments, the gravity driven flow culture configuration utilizes the medium level difference between the inlet and outlet well as well as engineering the fluidic resistances to achieve the desirable flow rate in nL/min regime. This provides the significant advantage of being able to “passively” flow culture medium for long periods of time (up to 4 days) without the use of bulky external pumps or tubes.
In further embodiments, the invention involves a microfluidic system to allow control of the cell culture environment for long-term time-lapse microscopy of adherent cells. As the trend towards “systems biology” continues, it will become increasingly important to study dynamic behavior in individual live cells as well as to improve the functionality and economics of high throughput live cell screening. According to specific embodiments of the invention, the invention provides a multiplexed microfluidic flow chamber allowing for time-lapse microscopy experimentation among other assays. The microfluidic chamber uses an artificial endothelial barrier to separate cells from flow channels. The device is formatted to a standard well plate, allowing liquid and cell samples to be directly pipetted into the appropriate inlet reservoirs using standard equipment. A custom pneumatic flow controller is then used to load the cells into the culture regions as well as to switch between different exposure solutions. A digital software interface can be used to allow a user to program specific inputs (pulses, ramps, etc.) over time to expose the cells to complex functions during time-lapse imaging.
Dynamic responses in living cells are the foundation for phenomena such as biological signal processing, gene expression regulation, differentiation, and cell division. In specific embodiments, the invention involves a system capable of controlling the cellular microenvironment in a multiplexed format compatible with current cell culture methods. Cell response can be quantified using high magnification fluorescence microscopy to derive kinetic information with sub-cellular resolution. This capability has broad applications in cellular systems biology where dynamic single cell response experiments are not currently practical.
2. Microfluidic Culture System and Array
The application referenced above (U.S. Ser. No. 11/994,997) discussed a variety of different cell culture configurations and fabrication techniques. Portions of the operation of the cell culture areas and materials are useful as background to the present discussion. In some examples therein, one or more micro culture areas are connected to a medium or reagent channel via a grid of fluidic passages (or diffusion inlets or conduits), wherein the grid comprises a plurality of intersection micro high fluidic resistance passages. In one discussed example, passages in the grid are about 1 to 4 μm in height, 25 to 50 μm in length and 5 to 10 μm in width, the grid allowing for more even diffusion between medium or reagent channels and the culture area and allowing for easier manufacturing and more even diffusion. The earlier application further discussed that the high fluidic resistance ratio between the microchamber and the perfusion/diffusion passages or grid (e.g., ratios in the range of about 10:1, 20:1 to 30:1) offers many advantages for cell culture such as: (1) size exclusion of cells; (2) localization of cells inside a microchamber; (3) promoting a uniform fluidic environment for cell growth; (4) ability to configure arrays of microchambers or culture areas; (4) ease of fabrication, and (5) manipulation of reagents without an extensive valve network. Examples were illustrated wherein a grid-like perfusion barrier can be much shorter than the culture area or can be near to or at the same height, according to specific embodiments of the invention and further wherein various configurations for culture devices were illustrated. The application also discussed a CAD drawing of a proposed 96-unit microfluidic bioreactor wherein each well was an SBS standard size (3.5 mm in diameter) in order to be compatible with existing robotic liquid handling systems and plate readers. The application also discussed several different configurations for an artificial sinusoid using both cut passages and grids and with a flow-around perfusion design.
Thus, the present invention according to specific embodiments of the invention provides a number of novel improved microfluidic configurations. In a first aspect, three wells are used for each otherwise independent cell culture system. In a second aspect, artificial sinusoids with artificial epithelial barriers are provided with just one (optionally shared or multiplexed) fluidic inlet and one (optionally shared or multiplexed) fluidic output, where the medium output also functions as a cellular input. In a third aspect, artificial sinusoids with artificial epithelial barriers with just one fluidic inlet and one fluidic output are divided into blocks with air channels provided between blocks. In a fourth aspect, air holes are provided in the well chamber above the cell culture area of a microfluidic cellular culture array, where the medium output also functions as a cellular input. In a fifth aspect, a multiplexed medium inlet structure and multiplexed cellular input structure are provided to connect inputs and outputs to blocks of artificial sinusoids. In a sixth aspect, a multiplexed medium inlet structure and larger shared cellular input structure are provided to connect inputs and outputs to blocks of artificial sinusoids. In a seventh aspect, artificial sinusoids are configured with non-open portions of an epithelial barrier to better localize cells, and with perfusions inlets surrounding a cell culture area and optionally also present near a cell inlet area of the sinusoid. In an eighth aspect, longer artificial sinusoid chambers are provided.
As discussed elsewhere, various modifications may be made to the cell-culture area as described above. Various configurations are possible for the epithelial barrier, such as a grid-like passage structure. Other variations will be suggested to those of skill in the art having the teachings provided herein.
The structures disclosed above can also be adapted to systems using more or fewer wells on a standard microtiter well plate, such as those described in referenced documents and in other examples herein.
3. Example Device Operation
Cell Loading
Cell loading in specific embodiments of the invention can utilize the rapid surface tension flow between the cell inlet and the flow inlet. In this method, the cell inlet reservoir (upper and lower) is aspirated of its priming solution. Then, the flow inlet upper reservoir is aspirated. An amount (e.g., Five microliters) of cell suspension (e.g., trypsinized HeLa human cancer cell line, 5×10 5 cells/ml) is dispensed into the cell inlet lower reservoir. The flow inlet lower reservoir is aspirated, causing liquid to flow from cell inlet to flow inlet via surface tension/capillary force. Cell loading in various configurations can be completed in approximately 2-5 minutes. The cell loading reservoir is then washed with medium (e.g., Dulbecco's Modified Eagle's Medium, DMEM) and filled with e.g., 50-100 microliters of clean medium. At this state, the plate is was placed in a controlled culture environment for a period (e.g., 37 C., 5% CO2 incubator for 2-4 hours) to allow for cell attachment.
While such loading is effective for some microfluidic cell culture devices, in a presently preferred embodiment, a proprietary pneumatic manifold, as described elsewhere herein, is mated to the plate and pneumatic pressure is applied to the cell inlet area for more effective cell loading. For particular cell systems, it has been found that overall cell culture area design can be made more effective when it is not necessary to allow for passive cell loading.
Pressurized cell loading in a system according to specific embodiments of the invention has been found to be particularly effective in preparing cultures of aggregating cells (e.g., solid tumor, liver, muscle, etc.). Pressurized cell loading also allows structures with elongated culture regions, e.g., as shown in
Fluid Flow and Operation: Gravity and Surface Tension Flow
The format of the microfluidic plate design allows two automation-friendly flow modalities dependent on the extent of dispensing/aspiration. The first is surface tension mediated flow. In this case, when the lower reservoir is aspirated in either one of the wells, the capillary force of the fluid/air interface along with the wetted surfaces (glass, silicone, acrylic) will rapidly draw liquid in from the opposing well until the lower reservoir is filled (or in equilibrium with the opposing lower reservoir). This effect is useful for microfluidic flows as it is only evident when the reservoir diameter is small and the flow volumes are small. In an example array design, the lower reservoir wells are 1-2 mm in diameter, and with a total flow volume of approximately 3-5 microliters. Since the microfluidic channel volume is only 0.2 microliters, this mechanism is well suited for cell loading and cell exposures.
The second mechanism is gravity driven perfusion, which is well suited for longer term flows, as this is dependent on the liquid level difference and not the reservoir dimensions. According to specific embodiments of the invention, this may be accomplished by adding more liquid into one reservoir (typically filling near the top of the upper reservoir). The fluidic resistance through the microfluidic channels will determine how long (e.g., 24 hours) to reach equilibrium between the wells and thus determine how often wells should be refilled.
Changing Gravity Flow Rate via Liquid Level
The gravity perfusion rate is also responsive to the liquid level difference between the two upper reservoir wells as illustrated in
Controlling Gravity Perfusion Rate Via Plate Tilt Angle
According to specific embodiments of the invention, the liquid height difference between the inlet/outlet wells across the plate can also be precisely controlled using a mechanical tilting platform. In this implementation, it is possible to maintain a constant flow rate over time, as well as back-and-forth flow with different forward and reverse times (i.e. blood flow). In the example illustrated in
In an example system, perfusion cell culture can be initiated by filling the flow inlet reservoir with 200-300 microliters of fresh medium (e.g., DMEM supplemented with 10% fetal bovine serum) and aspirating the cell inlet upper reservoir. The liquid level difference between the flow inlet and cell inlet wells will then cause a continuous gravity driven flow through the attached cells. For sustained culture, the flow inlet well is refilled and the cell inlet well aspirated during a period depending on fluidic resistance and reservoir volumes (e.g., every 24 hours).
Cell Assay and/or Observation
Cell assay can be performed directly on the microfluidic cell culture using standard optically based reagent kits (e.g. fluorescence, absorbance, luminescence, etc.). For example a cell viability assay utilizing conversion of a substrate to a fluorescent molecule by live cells has been demonstrated (CellTiter Blue reagent by Promega Corporation). The reagent is dispensed into the flow inlet reservoir and exposed to the cells via gravity perfusion over a period of time (e.g., 21 hours). For faster introduction of a reagent or other fluid, the new fluid can be added to the flow inlet reservoir followed by aspiration of the cell inlet reservoir.
Data can be collected directly on the cells/liquid in the microfluidic plate, such as placing the plate into a standard fluorescence plate reader (e.g., Biotek Instruments Synergy 2 model). In some reactions, the substrate may diffuse into the outlet medium, and therefore be easily detected in the cell inlet reservoir. For cell imaging assays, the plate can be placed on a scanning microscope or high content system. For example, an automated Olympus IX71 inverted microscope station can be used to capture viability of cultured liver cells with a 20× objective lens.
By repeatedly filling/aspirating the wells, cells can be maintained for long periods of time with minimal effort (e.g. compared to standard “bioreactors” which require extensive sterile preparation of large fluid reservoirs that cannot be easily swapped out during operation).
4. Automated Systems
Example 1
Because the top piece containing the well structures is injection molded, the bottom of the wells can be flat, rounded or tapered. One particular desired feature is that the bottom of the top piece, which covers the microfluidic structures, is as flat as practically to assist uniform molding across the array. According to specific embodiments of the invention, the bottom of the top piece can be chemically or mechanically or otherwise modified or primed by a reagent (such as Sylgard Primecoat) or an abrasive surface (sanding) or laser so the soft polymers adhere to the bottom of the top piece after the molding process. This treatment of the surface is indicated by the heavy line.
6. Example 2
After cooling the compartments down to approximately room temperature, the acrylic sheet with the soft polymer is detached from the mold and a microfluidic cell culture array as described herein is truthfully molded onto the soft polymer.
To protect the soft polymer surface from contaminations from following processes, a surface protection tape (e.g., Ultron Blue Adhesive Plastic Film 80 micron) is optionally applied to the top of the surface of the elastomer by a roller.
Integrated Systems
Integrated systems for the collection and analysis of cellular and other data as well as for the compilation, storage and access of the databases of the invention, typically include a digital computer with software including an instruction set for sequence searching and/or analysis, and, optionally, one or more of high-throughput sample control software, image analysis software, collected data interpretation software, a robotic control armature for transferring solutions from a source to a destination (such as a detection device) operably linked to the digital computer, an input device (e.g., a computer keyboard) for entering subject data to the digital computer, or to control analysis operations or high throughput sample transfer by the robotic control armature. Optionally, the integrated system further comprises valves, concentration gradients, fluidic multiplexors and/or other microfluidic structures for interfacing to a microchamber as described.
Readily available computational hardware resources using standard operating systems can be employed and modified according to the teachings provided herein, e.g., a PC (Intel x86 or Pentium chip-compatible DOS,™ OS2,™ WINDOWS,™ WINDOWS NT,™ WINDOWS95,™ WINDOWS98,™ LINUX, or even Macintosh, Sun or PCs will suffice) for use in the integrated systems of the invention. Current art in software technology is adequate to allow implementation of the methods taught herein on a computer system. Thus, in specific embodiments, the present invention can comprise a set of logic instructions (either software, or hardware encoded instructions) for performing one or more of the methods as taught herein. For example, software for providing the data and/or statistical analysis can be constructed by one of skill using a standard programming language such as Visual Basic, Fortran, Basic, Java, or the like. Such software can also be constructed utilizing a variety of statistical programming languages, toolkits, or libraries.
Various programming methods and algorithms, including genetic algorithms and neural networks, can be used to perform aspects of the data collection, correlation, and storage functions, as well as other desirable functions, as described herein. In addition, digital or analog systems such as digital or analog computer systems can control a variety of other functions such as the display and/or control of input and output files. Software for performing the electrical analysis methods of the invention are also included in the computer systems of the invention.
Other Embodiments
Although the present invention has been described in terms of various specific embodiments, it is not intended that the invention be limited to these embodiments. Modification within the spirit of the invention will be apparent to those skilled in the art.
It is understood that the examples and embodiments described herein are for illustrative purposes and that various modifications or changes in light thereof will be suggested by the teachings herein to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the claims.
All publications, patents, and patent applications cited herein or filed with this submission, including any references filed as part of an Information Disclosure Statement, are incorporated by reference in their entirety.
This application is a continuation of U.S. patent application Ser. No. 12/348,907 filed Jan. 5, 2009 (now U.S. Pat. No. 9,376,658 issued Jun. 28, 2016), which claims priority from provisional patent application 61/037,297 filed Mar. 17, 2008 and from 61/018,882 filed Jan. 3, 2008, each incorporated herein by reference. This application discusses technology related to U.S. Ser. No. 11/994,997, filed Aug. 11, 2008 (now U.S. Pat. No. 9,260,688 issued Feb. 16, 2016), which is a National Stage Entry of PCT/US06/26364, filed Jul. 6, 2006 and which claims priority from provisional patent application 60/773,467 filed 14 Feb. 2006 and from provisional patent application 60/697,449 filed 7 Jul. 2005. This application discusses technology related to U.S. application Ser. No. 12/019,857, filed Jan. 25, 2008 (now U.S. Pat. 9,354,156 issued May 31, 2016),which claims priority to U.S. Provisional Patent Application No. 60/900,651 filed on Feb. 8, 2007. This application discusses technology related to U.S. application Ser. No. 11/648,2071, filed Dec. 29, 2006 (now U.S. Pat. 8,257,964 issued Sep. 4, 2012), which claims priority to U.S. Provisional Patent Application U.S. provisional patent application No. 60/756,399 filed on Jan. 4, 2006. All of these applications are incorporated herein by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
4055613 | Kapral | Oct 1977 | A |
4661455 | Hubbard | Apr 1987 | A |
4734373 | Bartal | Mar 1988 | A |
4748124 | Vogler | May 1988 | A |
5079168 | Amiot | Jan 1992 | A |
5153131 | Wolf et al. | Oct 1992 | A |
5310676 | Johansson et al. | May 1994 | A |
5330908 | Spaulding | Jul 1994 | A |
5376252 | Ekstrom et al. | Dec 1994 | A |
5416022 | Amiot | May 1995 | A |
5424209 | Kearney | Jun 1995 | A |
5437998 | Schwarz et al. | Aug 1995 | A |
5451524 | Coble et al. | Sep 1995 | A |
5462874 | Wolf et al. | Oct 1995 | A |
5565353 | Klebe et al. | Oct 1996 | A |
5589112 | Spaulding | Dec 1996 | A |
5593814 | Matsuda et al. | Jan 1997 | A |
5602028 | Minchinton | Feb 1997 | A |
5627070 | Gruenberg | May 1997 | A |
5637469 | Wilding et al. | Jun 1997 | A |
5641644 | Klebe | Jun 1997 | A |
5658797 | Bader | Aug 1997 | A |
5686301 | Falkenberg et al. | Nov 1997 | A |
5686304 | Codner | Nov 1997 | A |
5693537 | Wilson et al. | Dec 1997 | A |
5702941 | Schwarz | Dec 1997 | A |
5714384 | Wilson et al. | Feb 1998 | A |
5763261 | Gruenberg | Jun 1998 | A |
5763275 | Nagels et al. | Jun 1998 | A |
5763279 | Schwarz et al. | Jun 1998 | A |
5786215 | Brown et al. | Jul 1998 | A |
5793440 | Nakasaka et al. | Aug 1998 | A |
5801054 | Kiel et al. | Sep 1998 | A |
5866345 | Wilding et al. | Feb 1999 | A |
5882918 | Goffe | Mar 1999 | A |
5900361 | Klebe | May 1999 | A |
5912177 | Turner et al. | Jun 1999 | A |
5924583 | Stevens et al. | Jul 1999 | A |
5932315 | Lum et al. | Aug 1999 | A |
5942443 | Parce et al. | Aug 1999 | A |
6039897 | Lochhead et al. | Mar 2000 | A |
6048498 | Kennedy | Apr 2000 | A |
6096532 | Armstrong et al. | Aug 2000 | A |
6107085 | Coughlin et al. | Aug 2000 | A |
6153073 | Dubrow et al. | Nov 2000 | A |
6190913 | Singh | Feb 2001 | B1 |
6197575 | Griffith et al. | Mar 2001 | B1 |
6228635 | Armstrong et al. | May 2001 | B1 |
6238908 | Armstrong et al. | May 2001 | B1 |
6251343 | Dubrow et al. | Jun 2001 | B1 |
6274337 | Parce et al. | Aug 2001 | B1 |
6277642 | Mentzen et al. | Aug 2001 | B1 |
6297046 | Smith et al. | Oct 2001 | B1 |
6323022 | Chang et al. | Nov 2001 | B1 |
6326211 | Anderson et al. | Dec 2001 | B1 |
6403369 | Wood | Jun 2002 | B1 |
6410309 | Barbera-Guillem et al. | Jun 2002 | B1 |
6455310 | Barbera-Guillem | Sep 2002 | B1 |
6465243 | Okada et al. | Oct 2002 | B2 |
6468792 | Bader | Oct 2002 | B1 |
6481648 | Zimmermann | Nov 2002 | B1 |
6495104 | Unno et al. | Dec 2002 | B1 |
6518035 | Ashby et al. | Feb 2003 | B1 |
6534013 | Kennedy | Mar 2003 | B1 |
6548263 | Kapur et al. | Apr 2003 | B1 |
6551841 | Wilding et al. | Apr 2003 | B1 |
6555365 | Barbera-Guillem et al. | Apr 2003 | B2 |
6562616 | Toner et al. | May 2003 | B1 |
6569675 | Wall et al. | May 2003 | B2 |
6576458 | Sarem et al. | Jun 2003 | B1 |
6585744 | Griffith | Jul 2003 | B1 |
6585939 | Dapprich et al. | Jul 2003 | B1 |
6593136 | Geiss | Jul 2003 | B1 |
6637463 | Lei et al. | Oct 2003 | B1 |
6648015 | Chow | Nov 2003 | B1 |
6653124 | Freeman | Nov 2003 | B1 |
6673595 | Barbera-Guillem | Jan 2004 | B2 |
6756019 | Dubrow et al. | Jun 2004 | B1 |
6759245 | Toner et al. | Jul 2004 | B1 |
6794184 | Mohr et al. | Sep 2004 | B1 |
6811752 | Barbera-Guillem | Nov 2004 | B2 |
6821772 | Barbera-Guillem et al. | Nov 2004 | B2 |
6846668 | Garman et al. | Jan 2005 | B1 |
6857449 | Chow | Feb 2005 | B1 |
6908767 | Bader | Jun 2005 | B2 |
6915679 | Chien et al. | Jul 2005 | B2 |
6969166 | Clark et al. | Nov 2005 | B2 |
7005292 | Wilding et al. | Feb 2006 | B2 |
7018830 | Wilding et al. | Mar 2006 | B2 |
7022518 | Feye | Apr 2006 | B1 |
7067263 | Parce et al. | Jun 2006 | B2 |
7141386 | Dunfield et al. | Nov 2006 | B2 |
7155344 | Parce et al. | Dec 2006 | B1 |
7160687 | Kapur et al. | Jan 2007 | B1 |
7171983 | Chien et al. | Feb 2007 | B2 |
7192769 | Pykett et al. | Mar 2007 | B2 |
7223371 | Hayenga et al. | May 2007 | B2 |
7343248 | Parce et al. | Mar 2008 | B2 |
7745209 | Martin et al. | Jun 2010 | B2 |
7919319 | Jervis et al. | Apr 2011 | B2 |
8257964 | Hung et al. | Sep 2012 | B2 |
8673625 | Hung et al. | Mar 2014 | B2 |
8709790 | Hung et al. | Apr 2014 | B2 |
9206384 | Lee et al. | Dec 2015 | B2 |
9260688 | Hung et al. | Feb 2016 | B2 |
9353342 | Hung et al. | May 2016 | B2 |
9353343 | Hung et al. | May 2016 | B2 |
9354156 | Lee et al. | May 2016 | B2 |
9371929 | Hung et al. | Jun 2016 | B2 |
9376658 | Hung et al. | Jun 2016 | B2 |
9388374 | Hung et al. | Jul 2016 | B2 |
9428723 | Lee et al. | Aug 2016 | B2 |
9637715 | Hung | May 2017 | B2 |
20020039785 | Schroeder et al. | Apr 2002 | A1 |
20020108860 | Staats | Aug 2002 | A1 |
20020110905 | Barbera-Guillem et al. | Aug 2002 | A1 |
20020177221 | Nishiguchi et al. | Nov 2002 | A1 |
20030008388 | Barbera-Guillem et al. | Jan 2003 | A1 |
20030008389 | Carll | Jan 2003 | A1 |
20030030184 | Kim et al. | Feb 2003 | A1 |
20030040104 | Barbera-Guillem | Feb 2003 | A1 |
20030124623 | Yager et al. | Jul 2003 | A1 |
20030143727 | Chang | Jul 2003 | A1 |
20030156992 | Anderson et al. | Aug 2003 | A1 |
20030211012 | Bergstrom et al. | Nov 2003 | A1 |
20030215941 | Campbell et al. | Nov 2003 | A1 |
20040029266 | Barbera-Guillem | Feb 2004 | A1 |
20040043481 | Wilson | Mar 2004 | A1 |
20040072278 | Chou et al. | Apr 2004 | A1 |
20040096960 | Mehta et al. | May 2004 | A1 |
20040132175 | Vetillard et al. | Jul 2004 | A1 |
20040202579 | Larsson et al. | Oct 2004 | A1 |
20040229349 | Daridon | Nov 2004 | A1 |
20040238484 | Le Pioufle et al. | Dec 2004 | A1 |
20050009179 | Gemmiti et al. | Jan 2005 | A1 |
20050019213 | Kechagia et al. | Jan 2005 | A1 |
20050032208 | Oh | Feb 2005 | A1 |
20050072946 | Studer et al. | Apr 2005 | A1 |
20050101009 | Wilson et al. | May 2005 | A1 |
20050106717 | Wilson et al. | May 2005 | A1 |
20050169962 | Bhatia et al. | Aug 2005 | A1 |
20050214173 | Facer et al. | Sep 2005 | A1 |
20050221373 | Enzelberger et al. | Oct 2005 | A1 |
20050260745 | Domansky et al. | Nov 2005 | A1 |
20050266582 | Modlin et al. | Dec 2005 | A1 |
20060003436 | DiMilla et al. | Jan 2006 | A1 |
20060031955 | West et al. | Feb 2006 | A1 |
20060112438 | West et al. | May 2006 | A1 |
20060121606 | Ito et al. | Jun 2006 | A1 |
20060136182 | Vacanti et al. | Jun 2006 | A1 |
20060141617 | Desai et al. | Jun 2006 | A1 |
20060154361 | Wikswo et al. | Jul 2006 | A1 |
20060166354 | Wikswo et al. | Jul 2006 | A1 |
20060199260 | Zhang et al. | Sep 2006 | A1 |
20070026516 | Martin et al. | Feb 2007 | A1 |
20070084706 | Takayama et al. | Apr 2007 | A1 |
20070090166 | Takayama et al. | Apr 2007 | A1 |
20070122314 | Strand et al. | May 2007 | A1 |
20070128715 | Vukasinovic et al. | Jun 2007 | A1 |
20070243523 | Ionescu-Zanetti et al. | Oct 2007 | A1 |
20070264705 | Dodgson | Nov 2007 | A1 |
20070275455 | Hung et al. | Nov 2007 | A1 |
20080032380 | Kleis et al. | Feb 2008 | A1 |
20080038713 | Gao et al. | Feb 2008 | A1 |
20080085556 | Graefing et al. | Apr 2008 | A1 |
20080176318 | Wilson et al. | Jul 2008 | A1 |
20080194012 | Lee et al. | Aug 2008 | A1 |
20080227176 | Wilson | Sep 2008 | A1 |
20080233607 | Yu et al. | Sep 2008 | A1 |
20090023608 | Hung et al. | Jan 2009 | A1 |
20090123961 | Meyvantsson et al. | May 2009 | A1 |
20090148933 | Battrell et al. | Jun 2009 | A1 |
20090203126 | Hung et al. | Aug 2009 | A1 |
20100151571 | Vukasinovic et al. | Jun 2010 | A1 |
20100196908 | Opalsky et al. | Aug 2010 | A1 |
20100234674 | Wheeler et al. | Sep 2010 | A1 |
20120003732 | Hung et al. | Jan 2012 | A1 |
20120164036 | Stern et al. | Jun 2012 | A1 |
20130059322 | Hung et al. | Mar 2013 | A1 |
20130081757 | Hung et al. | Apr 2013 | A1 |
20130090268 | Hung et al. | Apr 2013 | A1 |
20130171679 | Lee et al. | Jul 2013 | A1 |
20130171682 | Hung et al. | Jul 2013 | A1 |
20140057311 | Kamm et al. | Feb 2014 | A1 |
20140090735 | Hung et al. | Apr 2014 | A1 |
20140099705 | Hung et al. | Apr 2014 | A1 |
20140287489 | Lee et al. | Sep 2014 | A1 |
20160075984 | Hung et al. | Mar 2016 | A1 |
20160312166 | Lee et al. | Oct 2016 | A1 |
20160327470 | Lee et al. | Nov 2016 | A1 |
20160333297 | Hung et al. | Nov 2016 | A1 |
20160333298 | Hung et al. | Nov 2016 | A1 |
20160340630 | Hung et al. | Nov 2016 | A1 |
20170267961 | Hung et al. | Sep 2017 | A1 |
Number | Date | Country |
---|---|---|
201803927 | Apr 2011 | CN |
19948087 | May 2001 | DE |
0155237 | Sep 1985 | EP |
0725134 | Aug 1996 | EP |
0890636 | Jan 1999 | EP |
1539263 | Jan 1979 | GB |
9115570 | Oct 1991 | WO |
0056870 | Sep 2000 | WO |
0060352 | Oct 2000 | WO |
0078932 | Dec 2000 | WO |
0192462 | Dec 2001 | WO |
03085080 | Oct 2003 | WO |
03098218 | Nov 2003 | WO |
2004059299 | Jul 2004 | WO |
2004106484 | Dec 2004 | WO |
2005035728 | Apr 2005 | WO |
2007008606 | Jan 2007 | WO |
2007008609 | Jan 2007 | WO |
2009089189 | Jul 2009 | WO |
2009102453 | Aug 2009 | WO |
2012024646 | Feb 2012 | WO |
Entry |
---|
Office action dated Feb. 20, 2018 in co-pending U.S. Appl. No. 15/163,398. |
Notice of allowance dated Feb. 2, 2018 in co-pending U.S. Appl. No. 15/161,665. |
European communication dated Apr. 3, 2012 in co-pending European patent application No. 06786499.1. |
International Search Report and Written Opinion dated Apr. 9, 2009 in PCT application No. PCT/US06/26364 (corresponding to U.S. Appl. No. 11/994,997). |
International Search Report and Written Opinion dated Jul. 30, 2009 in corresponding PCT application No. PCT/US2009/030168. |
European communication dated Oct. 21, 2013 in corresponding European patent application No. 09701350.2. |
International Search Report dated May 14, 2013 in co-pending PCT application No. PCT/US2013/024999. |
International Search Report dated Mar. 19, 2013 in co-pending PCT application No. PCT/US2012/067632. |
International Preliminary Report on Patentability dated Jun. 12, 2014 in co-pending PCT application No. PCT/US2012/067632. |
European communication dated Jul. 28, 2015 in co-pending European patent application No. 12852539.1. |
Japanese communication, with English translation, dated Nov. 17, 2015 in co-pending Japanese patent application No. 2015-503203. |
Chinese communication, with English translation, dated Jun. 20, 2016 in co-pending Chinese patent application No. 201380018324.1. |
Engineering Aspects of Food Biotechnology, Chapter 5, CRC Press: Boca Raton, FL, 2004, copyright 2014, p. 127, “Meet the Stem Cells; Production of Cultured Meat from a Stem Cell Biology Perspective”, Brinkhof, et al., 3 pages. |
Cellasic Corporation, Onix Application Note, “Microincubator for long term live cell microscopy”, Feb. 3, 2012, pp. 1-4. |
Optics Express, vol. 14, No. 13, Jun. 2006, pp. 6253-6256, “Fabrication of polymer microlens arrays using capillary forming with a soft mold of micro-holes array and UV-curable polymer”, Chang, et al. |
Lab Chip, 2007, vol. 7, pp. 641-643, published by the Royal Society of Chemistry, “Rapid fabrication of microchannels using microscale plasma activated templating (uPLAT) generated water molds”, Chao, et al. |
Lab on a Chip, 2007, vol. 7, pp. 763-769, “A hydrogel-based microfluidic device for the studies of directed cell migration”, Cheng, et al. |
Lab Chip, 2005, vol. 5, No. 4, pp. 401-406, published by The Royal Society of Chemistry, “Human neural stem growth and differentiation in a gradient-generating microfluidic device”, Chung, et al. |
Lab on a Chip, 2008, vol. 9, Iss.2 pp. 269-275, “Cell Migration into Scaffolds Under Co-culture Conditions in a Microfluidic Platform,” Chung et al. |
J. Biochem., vol. 130, pp. 367-376, (2001), “A Method for Micrometer Resolution Patterning of Primary Culture Neurons for SPM Analysis”, Degenaar, et al. |
Biotechnology and Bioengineering, vol. 89, No. 1, Jan. 5, 2005, pp. 1-8, “Continuous Perfusion Microfluidic Cell culture Array for High-Throughput Cell-Based Assays”, Hung, et al. |
Lab Chip, 2005, vol. 5, pp. 44-48, “A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array”, Hung, et al. |
Lab Chip, 2008, vol. 8, No. 1, pp. 34-57, published by The Royal Society of Chemistry, “Biomolecular gradients in cell culture systems”, Keenan, et al. |
Keenan et al., “A new method for studying gradient-induced neutrophil desensitization based on an open microfluidic chamber”, Lab Chip, 2010, vol. 10, pp. 116-122. |
Lab on a Chip, 2009, vol. 9, p. 1797-1800, “Selective and tunable gradient device for cell culture and chemotaxis study”, Kim, et al. |
Biotechnology and Bioengineering, vol. 97, No. 5, Aug. 1, 2007, pp. 1340-1346, “An Artificial Liver Sinusoid With a Microfluidic Endothelial-Like Barrier for Primary Hepatocyte Culture”, Lee, et al. |
Lab Chip, 2009, vol. 9, No. 1, pp. 164-166, published by The Royal Society of Chemistry, “Dynamic cell culture: a microfluidic function generator for live cell microscopy”, Lee, et al. |
Journal of the Association for Laboratory Automation (JALA), 2007, vol. 12, No. 6, pp. 363-367, “Microfluidic System of Automated Cell-Based Assays”, Lee, et al. |
Lee et al., “Microfluidic Systems for Live Cell Imaging”, Methods in Cell Biology, 2011, vol. 102, pp. 77-103. |
Lab Chip, 2003, vol. 3, pp. 318-323, published by the The Royal Society of Chemistry, “Fabrication of microfluidic mixers and artificial vasculatures using a high-brightness diode-pumped Nd: YAG laser direct write method”, Lim, et al. |
Biomed Microdevices (2008), vol. 10, pp. 499-507, “Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells”, Liu, et al. |
Biomaterials, 2008, vol. 29, No. 22, pp. 3237-3244, “A gel-free 3D microfluidic cell culture system”, Ong, et al. |
Lab on a Chip, 2007, vol. 7, pp. 1673-1680, “Gradient generation by an osmotic pump and the behavior of human mesenchymal stem cells under the fetal bovine serum concentration gradient”, Park, et al. |
Angew. Chem. Int. Ed., 2004. vol. 43, pp. 1531-1536, “Minimal Functional Model of Hemostasis in a Biomimetic Microfluidic system”, Runyon, et al. |
Biomedical Microdevices, 2003, vol. 5, No. 3, pp. 235-244, “Microfluidic Patterning of Cellular Biopolymer Matrices for Biomimetic 3-D Structures”, Tan, et al. |
Office Action dated Feb. 22, 2013 in co-pending U.S. Appl. No. 13/436,992. |
Office Action dated Sep. 6, 2013 in co-pending U.S. Appl. No. 13/436,992. |
Final Rejection dated Apr. 11, 2014 in co-pending U.S. Appl. No. 13/436,992. |
Office Action dated Nov. 6, 2014 in co-pending U.S. Appl. No. 13/436,992. |
Final Rejection dated Mar. 23, 2015 in co-pending U.S. Appl. No. 13/436,992. |
Office action dated Nov. 20, 2015 in co-pending U.S. Appl. No. 13/436,992. |
Final rejection dated Mar. 11, 2016 in co-pending U.S. Appl. No. 13/436,992. |
Office Action dated Jun. 19, 2015 in co-pending U.S. Appl. No. 14/221,615. |
Notice of Allowance dated Jan. 6, 2016 in co-pending U.S. Appl. No. 14/221,615. |
Notice of Allowance dated Apr. 11, 2016 in co-pending U.S. Appl. No. 14/221,615. |
Notice of Allowance dated Dec. 6, 2016 in co-pending U.S. Appl. No. 13/436,992. |
Office action dated Jul. 6, 2017 in co-pending U.S. Appl. No. 15/161,665. |
Office Action dated Feb. 23, 2017 in co-pending U.S. Appl. No. 15/175,749. |
Office action dated Nov. 1, 2017 in co-pending U.S. Appl. No. 15/175,749. |
Notice of allowance dated Jun. 11, 2018 in co-pending U.S. Appl. No. 15/163,398. |
Notice of allowance dated Jul. 5, 2018 in co-pending U.S. Appl. No. 15/163,818. |
Office action dated Jul. 10, 2018 in co-pending U.S. Appl. No. 15/175,749. |
Notice of allowance dated May 31, 2018 in co-pending U.S. Appl. No. 15/161,665. |
Final rejection dated Mar. 27, 2018 in co-pending U.S. Appl. No. 15/175,749. |
Office action dated Mar. 21, 2018 in co-pending U.S. Appl. No. 15/163,818. |
Office action dated Apr. 18, 2018 in co-pending U.S. Appl. No. 15/175,449. |
Ex parte Quayle action mailed Apr. 24, 2018 in co-pending U.S. Appl. No. 15/163,398. |
Ex parte Quayle action mailed May 21, 2018 in co-pending U.S. Appl. No. 15/163,818. |
Notice of allowance dated Aug. 6, 2018 in co-pending U.S. Appl. No. 15/161,665. |
Notice of allowance dated Sep. 12, 2018 in co-pending U.S. Appl. No. 15/175,449. |
Number | Date | Country | |
---|---|---|---|
20160289623 A1 | Oct 2016 | US |
Number | Date | Country | |
---|---|---|---|
61037297 | Mar 2008 | US | |
61018882 | Jan 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12348907 | Jan 2009 | US |
Child | 15163368 | US |